SIX · ROP.SW
Roche Holding AG
CHF 401.70+CHF 2.90 (+0.73%)
Roche Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.67% below the high.
Loading market information…
SIX · ADXN.SW · CHF
Stock price, earnings
Quote as of Oct 29, 2026, 03:38 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CHF. Historical prices are not a forecast.
Addex Therapeutics Ltd’s quoted price sits in the lower half of its reported 52-week range, 70.14% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Addex Therapeutics Ltd’s next earnings report is currently expected on Nov 9, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Addex Therapeutics Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Based in Geneva, Switzerland, the firm's core research centers on identifying oral small molecule allosteric modulators that interact with G-protein coupled receptors. Its leading clinical programs feature Dipraglurant, intended for the treatment of levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, targeting epilepsy and various other neurological disorders; and GABAB PAM, developed to combat addiction. Addex has established strategic licensing and collaborative partnerships with organizations including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002, the company changed its name from Addex Pharmaceuticals Ltd to its current designation in March 2012.
Latest available per-share figures in CHF. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:46 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | Apr 7, 2025 | -CHF 0.01-23.0% vs estimate | CHF 1.51K-98.99% vs estimate |
|---|
| Q3 2024 | Nov 22, 2024 | -CHF 0.02-55.6% vs estimate | CHF 58.35K-61.1% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CHF 401.70+CHF 2.90 (+0.73%)
Roche Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.67% below the high.
CHF 132.30+CHF 3.08 (+2.38%)
Novartis AG’s quoted price sits in the upper half of its reported 52-week range, 1.53% below the high.
CHF 640.80+CHF 11.00 (+1.75%)
Lonza Group AG’s quoted price sits in the upper half of its reported 52-week range, 0.12% below the high.
CHF 58.70CHF 0.00 (0.0%)
Cosmo Pharmaceuticals N.V.’s quoted price sits in the lower half of its reported 52-week range, 54.64% below the high.
CHF 71.50-CHF 1.90 (-2.59%)
Basilea Pharmaceutica AG’s quoted price sits in the upper half of its reported 52-week range, 5.67% below the high.
CHF 15.60+CHF 0.64 (+4.28%)
Santhera Pharmaceuticals Holding AG’s quoted price sits in the upper half of its reported 52-week range, 17.2% below the high.
CHF 9.13+CHF 0.29 (+3.28%)
Newron Pharmaceuticals S.p.A.’s quoted price sits in the lower half of its reported 52-week range, 71.33% below the high.
CHF 2.25-CHF 0.02 (-0.88%)
EvoNext Holdings S.A.’s quoted price sits in the upper half of its reported 52-week range, 17.88% below the high.
